Hereditary breast cancer

Current Problems in Surgery

Volumn 38, Issue 6, 2001, Pages 387-480

  Robson, Mark E ^a   Boyd, Jeff ^a   Borgen, Patrick I ^b   Cody III, Hiram S ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ANIMAL; BREAST TUMOR; FAMILIAL CANCER; FEMALE; FLOW CYTOMETRY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; HUMAN; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MUTATION; OVARIECTOMY; OVARY TUMOR; PENETRANCE; PEUTZ JEGHERS SYNDROME; REVIEW; RISK FACTOR; SEGMENTAL MASTECTOMY; TUMOR SUPPRESSOR GENE;

ANIMALS; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENES, BRCA1; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LI-FRAUMENI SYNDROME; MASTECTOMY; MASTECTOMY, SEGMENTAL; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARIECTOMY; PENETRANCE; PEUTZ-JEGHERS SYNDROME; POPULATION SURVEILLANCE; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0035380715     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-3840(01)70035-4     Document Type: Article

References (431)

1. Bishop JM. Cancer: the rise of the genetic paradigm. Genes Dev 1995;9:1309-15.
2. Boveri T. Zur Frage der Entstehung maligner Tumoren. Jena: Verlag von Gustav Fischer; 1914.
3. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-9.
4. Spector D, Varmus HE, Bishop JM. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. Proc Natl Acad Sci U S A 1978;75:4102-6.
5. Weinberg RA. Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis. Cancer Res 1989;49:3713-21.
6. Boyd J, Barrett JC. Genetic and cellular basis of multistep carcinogenesis. Pharmacol Ther 1990;46:469-86.
7. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-48.
8. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
9. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139-46.
10. Hunter T. Cooperation between oncogenes. Cell 1991;64:249-70.
11. Weinberg RA. Tumor suppressor genes. Science 1991;254:1138-46.
12. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-8.
13. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
14. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997;386:761-3.
15. Nowell P. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
16. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-9.
17. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
18. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
19. Fearon ER, Cho KR, Nigro JM, Kern SE, Simon JW, Ruppert JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56.
20. Bishop JM. Cellular oncogenes and retroviruses. Annu Rev Biochem 1983;52:301-54.
21. Gutkind JS. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 1998;17:1331-42.
22. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-413.
23. Bos JL. ras Oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
24. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233-9.
25. Aaronson SA. Growth factors and cancer. Science 1991;254:1146-53.
26. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
27. Schechter AL. The neu oncogene: an ere-B-related gene encoding a 185,000-M, tumour antigen. Nature 1984;312:513-6.
28. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
29. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83.
30. Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 1999;81:1419-25.
31. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
32. Haber DA, Housman DE. Rate limiting steps: the genetics of pediatric cancers. Cell 1991;64:5-8.
33. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
34. National Human Genome Research Institute. Breast Cancer Information Core. Available at: http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/.
35. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallic BL, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305:779-84.
36. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A 1991;88:10657-61.
37. Deng G, Chen L-C, Schott DR, Thor A, Bhargava V, Ljung B-M, et al. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 1994;54:499-505.
38. Casey G, Lopez ME, Ramos JC, Plummet SJ, Arboleda MJ, Shaughnessy M, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
39. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997;57:3657-9.
40. Bignell GR, Barfoot R, Seal S, Collins N, Warren W, Stratton MR. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res 1998;58:1384-6.
41. Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster ADB, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 1996;56:2726-32.
42. Mant D, Vessey MP. Epidemiology of breast cancer. In: Bland KI, Copeland EM, editors. The breast: comprehensive management of benign and malignant diseases. Philadelphia: Saunders; 1991. p. 235-46.
43. Williams WR, Anderson DE. Genetic epidemiology of breast cancer: segregation analysis of 200 Danish pedigrees. Genet Epidemiol 1984;1:7-20.
44. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 1988;85:3044-8.
45. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, et al. Family history, age, and risk of breast cancer: prospective data from the Nurses' Health Study. JAMA 1993;270:338-43.
46. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. JAMA 1993;270:1563-8.
47. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24.
48. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
49. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, et al. Familial breast-ovarian cancer locus on chromosome 17q1 2-q23. Lancet 1991;338:82-3.
50. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families: the Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
51. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995;56:254-64.
52. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
53. Narod S, Ford D, Devilee P, Barkardottir RB, Eyfjord J, Lenoir G, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995;57:957-8.
54. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
55. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994;8:387-91.
56. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392-8.
57. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
58. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
59. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
60. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
61. Futreal PA, Söderkvist P, Marks JR, Iglehart JD, Cochran C, Barrett JC, et al. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res 1992;52:2624-7.
62. Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, et al. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 1993;53:3382-5.
63. Cropp CS, Champeme MH, Lidereau R, Callahan R. Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res 1993;53:5617-9.
64. Cropp CS, Nevanlinna HA, Pyrhonen S, Stenman UH, Salmikangas P, Albertsen H, et al. Evidence for involvement of BRCA1 in sporadic breast carcinomas. Cancer Res 1994;54:2548-51.
65. Champeme M-H, Mazoyer S, Stoppa-Lyonnet D, Bieche I, Ithier G, Sobol H, et al. Sublocalization of the smallest regions of deletion on chromosome 17q1 2-q23 in sporadic primary breast tumors. Oncol Rep 1995;2:825-32.
66. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
67. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997;57:3347-50.
68. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors [see comments]. J Natl Cancer Inst 2000;92:564-9.
69. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999;21:236-40.
70. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992;2:128-31.
71. Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995; 1:539-44.
72. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
73. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
74. Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families [see comments]. Am J Hum Genet 1997;60:1041-9.
75. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341-5.
76. Huusko P, Paakkonen K, Launonen V, Poyhonen M, Blanco G, Kauppila A, et al. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 1998;62:1544-8.
77. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998;63:1341-51.
78. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
79. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
80. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds [see comments]. Nat Genet 1996;12:333-7.
81. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120-2.
82. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123-5.
83. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-8.
84. Cancer risks in BRCA2 mutation carriers: the Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
85. Hamann U, Herbold C, Costa S, Solomayer EF, Kaufmann M, Bastert G, et al. Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res 1996;56:1988-90.
86. Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, et al. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 1997;57:5469-74.
87. Osborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res 2000;60: 3706-12.
88. Weber BHF, Brohm M, Stec I, Backe J, Caffier H. A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 1996;59:962-4.
89. Collins N, Wooster R, Stratton MR. Absence of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 1997;76:1150-6.
90. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, et al. Consistent loss of the wild-type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-5.
91. Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V, et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995;55:4830-2.
92. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126-8.
93. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-90.
94. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143-9.
95. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, et al. The founder mutations 185delAG and 5382insc in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-14.
96. Fodor FH, Weston A, Bleiweiss I J, McCurdy LD, Walsh MM, Tartter PI, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998;63:45-51.
97. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7.
98. Thorlacius S, Sigurdsson S, Bjamadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population [see comments]. Am J Hum Genet 1997;60:1079-84.
99. Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, et al. The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 1998;63:272-4.
100. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, et al. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996;272:123-6.
101. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner [published erratum appears in Cancer Res 1996;56:4074]. Cancer Res 1996;56:3168-72.
102. Coene E, Van Oostveldt P, Willems K, van Emmelo J, De Potter CR. BRCA1 is localized in cytoplasmic tube-like invaginations in the nucleus. Nat Genet 1997;16:122-4.
103. Koonin EV, Altschul S, Bork P. BRCA1 protein products: functional motifs. Nat Genet 1996;13:266-8.
104. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996;382:678-9.
105. Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A 1996;93:13595-9.
106. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997;94:5605-10.
107. Ouchi T, Monteiro AA, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 1998;95:2302-6.
108. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, et al. The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;11:17-26.
109. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of BRCA1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice [published erratum appears in Genes Dev 1996;10:365]. Genes Dev 1995;9:2712-22.
110. Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, et al. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 1996;7:711-5.
111. Gudas JM, Li T, Nguyen H, Jensen D, Rauscher FJ, Cowan KH. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 1996;7:717-23.
112. Gudas JM, Nguyen H, Li T, Cowan KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995;55:4561-5.
113. Spillman MA, Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 1996;13:1639-45.
114. Rao VN, Shao N, Ahmad M, Reddy ES. Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 1996;12:523-8.
115. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King M-C, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996;12:298-302.
116. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996;13:1-7.
117. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75.
118. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425-35.
119. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, et al. The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 1996;85:1009-23.
120. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of BRCA1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 1997;16:298-302.
121. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of BRCA1, BRCA2, BRCA1/BRCA2, BRCA1/p53, and BRCA2/p53 nullizygous embryos. Genes Dev 1997;11:1226-41.
122. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281: 1009-12.
123. Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1 controls homology-directed DNA repair. Mol Cell 1999;4:511-8.
124. Hsu LC, White RL. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci U S A 1998;95:12983-8.
125. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389-95.
126. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-86.
127. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999;4:1093-9.
128. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6.
129. Li S, Ting NS, Zheng L, Chen PL, Ziv Y, Shiloh Y, et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 2000;406:210-5.
130. Lee J-S, Collins KM, Brown AL, Lee C-H, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000;404:201-4.
131. Bertwistle D, Swirl S, Marston NJ, Jackson LE, Crossland S, Crompton MR, et al. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 1997;57:5485-8.
132. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 1998;95:5287-92.
133. Wang SC, Lin SH, Su LK, Hung MC. Changes in BRCA2 expression during progression of the cell cycle. Biochem Biophys Res Commun 1997;234:247-51.
134. Rajan JV, Wang M, Marquis ST, Chodosh LA. BRCA2 is coordinately regulated with BRCA1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A 1996;93:13078-83.
135. Connor F, Smith A, Wooster R, Stratton M, Dixon A, Campbell E, et al. Cloning, chromosomal mapping and expression pattern of the mouse BRCA2 gene. Hum Mol Genet 1997;6:291-300.
136. Rajan JV, Marquis ST, Gardner HP, Chodosh LA. Developmental expression of BRCA2 colocalizes with BRCA1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol 1997;184:385-401.
137. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2, Nature 1997;386:772-3.
138. Sharan SK, Morimatsu M, Albrecht U, Lim D-S, Regel E, Dinh C, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997;386:804-10.
139. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998;2:317-28.
140. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, et al. BRCA2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997;11:1242-52.
141. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, et al. Tumorigenesis and a DNA repair defect in mice with a truncating BRCA2 mutation. Nat Genet 1997;17:423-30.
142. Friedman LS, Thistlethwaite FC, Patel KJ, Yu VP, Lee H, Venkitaraman AR, et al. Thymic lymphomas in mice with a truncating mutation in BRCA2. Cancer Res 1998;58:1338-43.
143. Patel KJ, Hu VPCC, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, et al. Involvement of BRCA2 in DNA repair. Mol Cell 1998;1:347-57.
144. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978-85.
145. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment [in process citation]. Proc Natl Acad Sci U S A 1998;95:5287-92.
146. Futamura M, Arakawa H, Matsuda K, Katagiri T, Saji S, Miki Y, et al. Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1. Cancer Res 2000;60:1531-5.
147. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: familial syndrome? Ann Intern Med 1969;71:747-52.
148. Lynch HT, Mulcahy GM, Harris RE, Guirgis HA, Lynch JF. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinomas. Cancer 1978;41:2055-64.
149. Malkin D. The Li-Fraumeni syndrome. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 1998. p. 393-407.
150. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
151. Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
152. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
153. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;348:747-9.
154. Linzer DIH, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
155. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-3.
156. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
157. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-5.
158. Chen PL, Chen YM, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990;250:1576-80.
159. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
160. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
161. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
162. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708-11.
163. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-30.
164. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
165. Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998;282:290-3.
166. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
167. Reed M, Woelker B, Wang P, Wang Y, Anderson ME, Tegtmeyer P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci USA 1995;92:9455-9.
168. Lee S, Elenbaas B, Levine A, Griffith J. p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995;81:1013-20.
169. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A 1996;93:4827-32.
170. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent Gl arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994;8:2540-51.
171. 2 arrest after DNA damage. Science 1998;282:1497-501.
172. Hartwell L, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997;278:1064-8.
173. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
174. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282:1893-7.
175. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJA, Gittelsohn AM, Booker SV, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987;316:1511-4.
176. Spigelman AD, Murray V, Phillips RKS. Cancer and the Peutz-Jeghers syndrome. Gut 1989;30:1588-90.
177. Boardman LA, Thibodeau SN, Schaid DJ, Lindor NM, McDonnell SK, Burgart LJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998;128:896-9.
178. Hemminki A, Tomlinson I, Markie D, Jarvinen H, Sistonen P, Bjorkqvist A-M, et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997;15:87-90.
179. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
180. Jenne DE, Reimann H, Nezu J, Friedel W, Loft S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38-43.
181. Su J Y, Erikson E, Maller JL. Cloning and characterization of a novel serine/threonine protein kinase expressed in early Xenopus embryos. J Biol Chem 1996;271:14430-7.
182. Hanssen AM, Fryns JP. Cowden syndrome. J Med Genet 1995;32:117-9.
183. Lloyd KM, Dennis M. Cowden's disease: a possible new symptom complex with multiple system involvement. Ann Intern Med 1963;58:136-42.
184. Brownstein MH, Mehregan AH, Bikowski JB, Lupulescu A, Patterson JC. The dermatopathology of Cowden's syndrome. Br J Dermatol 1979;100:667-73.
185. Starink TM, Meijer CJLM, Brownstein MH. The cutaneous pathology of Cowden's syndrome: new findings. J Cutan Pathol 1985;12:83-93.
186. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
187. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
188. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
189. Kong D, Suzuki A, Zou T-T, Sakurada A, Kemp LW, Wakatsuki S, et al. PTEN is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
190. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
191. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997;57:5254-7.
192. Wang SI, Pue J, Li J, Bruce JN, Cairns P, Sidransky D, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6.
193. Rasheed BKA, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 1997;57:4187-90.
194. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
195. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-8.
196. Wang SI, Parsons R, Ittman M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4: 811-5.
197. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-7.
198. Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI, Liu W. Mutation analysis of the putative tumor suppressor PTEN/MMAC 1 in human ovarian cancer. Int J Oncol 1998;13:101-5.
199. Dahia PL, Marsh DJ, Zheng Z, Zedinius J, Komminoth P, Frisk T, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997;57:4710-3.
200. +/-mice. Cancer Res 2000;60:3605-11.
201. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-8.
202. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 1998;143:1375-83.
203. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998;95:15587-91.
204. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995;87:1114-25.
205. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer: an updated review. Cancer 1996;78:1149-67.
206. Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.
207. Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516-20.
208. Aamio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in the hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995;64:430-3.
209. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-7.
210. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Bum J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10.
211. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-85.
212. Itoh H, Houlston RS, Harocopos C, Slack J. Risk of cancer death in first-degree relatives of patients with hereditary non-polyposis cancer syndrome (Lynch type II): a study of 130 kindreds in the United Kingdom. Br J Surg 1990;77:1367-70.
213. Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern PG, Kushi LH. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history. Genet Epidemiol 1993;10:235-44.
214. Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 1996;77:1836-43.
215. Boyd J, Rhei E, Federici MG, Borgen PI, Watson P, Franklin B, et al. Male breast cancer and the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 1999;53:87-91.
216. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 1995;33:90-104.
217. Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 1991;90:606-13.
218. Peltomaki P, Vasen HFA, Cancer ICGoHNC. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 1997;113:1146-58.
219. Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, et al. Germline msh6 mutations in colorectal cancer families. Cancer Res 1999;59:5068-74.
220. Wijnen J, de Leeuw W, Vasen H, van der Klift H, Moiler P, Stormorken A, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23:142-4.
221. Wu Y, Berends JW, Mensink RGJ, Kempinga C, Sijmons RH, ven der Zee AGJ, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 1999;65:1291-8.
222. Bapat B, Xia L, Madlensky L, Mitri A, Tonin P, Narod SA, et al. The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. Am J Hum Genet 1996;59: 736-9.
223. Kolodner RD, Hall NR, Lipford J, Kane MF, Rao MRS, Mordson P, et al. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations. Genomics 1994;24:516-26.
224. Fishel R, Kolodner R. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Develop 1995;5:382-95.
225. Kolodner RD. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 1995;20:397-401.
226. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a routs homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
227. Hemminki A, Peltomaki P, Mecklin J-P, Jarvinen H, Salovaara R, Nystrom-Lahti M, et al. Loss of the wild-type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 1994;8:405-410.
228. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995;9:48-55.
229. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994;54:5059-63.
230. Modrich P. Mismatch repair, genetic stability, and cancer. Science 1994;266:1959-60.
231. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999;59:462-6.
232. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa J-PJ, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
233. Leung SY, Yuen ST, Chung LP, Chu KM, Chan ASY, Ho JCI. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999;59:159-64.
234. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
235. Parsons R, Myeroff L, Liu B, Willson JKV, Markowitz S, Kinzler KW, et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 1995;55:5548-50.
236. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
237. Ouyang H, Shiwaku HO, Hagiwara H, Miura K, Abe T, Kato Y, et al. The insulin-like growth factor H receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res 1997;57:1851-4.
238. Scwartz S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1999;59:2995-3002.
239. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
240. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, et al. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 1998;20:62-5.
241. Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, et al. The APCI1307K allele and breast cancer risk. Nat Genet 1998;20:13-4.
242. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6.
243. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999;64:1371-7.
244. Coughlin SS, Piper M. Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:1023-32.
245. Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
246. Xie D, Shu X-O, Deng Z, Wen W-Q, Creek KE, Dai Q, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000;92:412-7.
247. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000;60:1062-9.
248. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-42.
249. Mu H, Newman B, Rousseau C, Payne S, Gordon K, Gold D et al. Frequency of breast cancer attributable to BRCA1 and BRCA2 in a population-based series of Caucasian and African-American women [abstract]. Am J Hum Genet 1999; 4:63.
250. Malone KE, Daling JR, Neal C, Surer NM, O'Brien C, Cushing-Haugen K, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1393-402.
251. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-9.
252. Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999;91:2112-7.
253. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435-41.
254. Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996;347:1643-5.
255. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179-83.
256. Gershoni-Baruch R, Dagan E, Fried G, Bruchim B, Sverdlov-Shifi R, Zelicksson G, et al. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer 2000;36:983-6.
257. Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1997;1:47-51.
258. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-5.
259. Domm A, Hovig E, Trope C, Inganas M, Moiler P. Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur J Cancer 1999;35:779-81.
260. Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B, et al. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet 1997;60:1242-6.
261. Frank TS, Gumpper K, Manley SA, Ward B. The proportion of atypical protein-truncating mutations in BRCA1 and BRCA2 in women of Ashkenazi ancestry [abstract]. Breast Cancer Res Treat 1998;50:296.
262. Robson ME, Offit K. New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet 1997;350:117-8.
263. Schubert EL, Mefford HC, Dann JL, Argonza RH, Hull J, King MC. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genet Test 1997;1:41-6.
264. Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 2000;67:841-50.
265. BRCA1 Exon 13 Duplication Screening Group. The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 2000;67:207-12.
266. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:2984-6.
267. Warren W, Eeles RA, Ponder BA, Easton DF, Averill D, Ponder MA, et al. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene 1992;7:1043-6.
268. Preudhomme C, Fenaux P, Peyrat JP, Foumier J, Bonneterre J, Vennin P. Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France. Eur J Cancer 1993;29:1476-8.
269. Patel UA, Perry M, Crane-Robinson C. Screening for germline mutations of the p53 gene in familial breast cancer patients. Eur J Clin Invest 1995;25:132-7.
270. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000;60:1062-9.
271. Angele S, Hall J. The ATM gene and breast cancer: Is it really a risk factor? Mutat Res 2000;462:167-78.
272. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst 2000;92:795-802.
273. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997;15:307-10.
274. Vorechovsky I, Luo L, Lindblom A, Negrini M, Webster AD, Croce CM, et al. ATM mutations in cancer families. Cancer Res 1996;56:4130-3.
275. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 2000;66:494-500.
276. Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998;62:334-45.
277. Carroll BT, Couch FJ, Rebbeck TR, Weber BL. Polymorphisms in PTEN in breast cancer families. J Med Genet 1999;36:94-6.
278. FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, et al. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 1998;17:727-31.
279. Chen J, Lindblom P, Lindblom A. Astudy of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 1998;102:124-5.
280. Tsou HC, Teng DH, Ping XL, Brancolini V, Davis T, Hu R, et al. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 1997;61:1036-43.
281. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
282. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review, 1973-1997. Bethesda (MD): National Cancer Institute; 2000.
283. Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997;336:1416-21.
284. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
285. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90:1138-45.
286. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
287. Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998;58:1839-42.
288. Verhoog LC, Brekelmans CTM, Seynaeve C, van den Bosch LMC, Dahrnen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
289. Bignon YJ, Fonck Y, Chassagne MC. Histoprognostic grade in tumours from families with hereditary predisposition to breast cancer [commentary]. Lancet 1995;346:258.
290. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
291. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study [see comments]. Cancer 1998;83:2335-45.
292. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 1998;29:1140-4.
293. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200-5.
294. Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 1999;91:469-73.
295. Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998;58:1839-42.
296. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de PB, Peyrat JP, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998;58:1588-92.
297. Eisinger F, Nogues C, Birnbaum D, Jacquemier J, Sobol H. BRCA1 and medullary breast cancer. JAMA 1998;280:1227-8.
298. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642-9.
299. Agnarsson BA, Jonasson JG, Bjomsdottir IB, Barkardottir RB, Egilsson V, Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 1998;47:121-7.
300. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997;44:275-7.
301. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-9.
302. Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999;17:3396-402.
303. Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998;17:1681-9.
304. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-7.
305. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet 1993;341:184-5.
306. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994; 81:1512-5.
307. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16:397-404.
308. Gaffney DK, Brohet RM, Lewis CM, Holden JA, Buys SS, Neuhausen SL, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998;47:129-36.
309. Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 2000;59:185-92.
310. Pierce L, Strawderman M, Narod S, Olivotto I, Eisen A, Dawson L, et al. No deleterious effects of radiotherapy in women who are heterozygote for a BRCA-1 or BRCA-2 mutation following breast conservation therapy. J Clin Oncol 2000;18:3360-9.
311. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients: Institut Curie Breast Cancer Group [letter]. Lancet 1998;352:541.
312. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642-9.
313. Foulkes WD, Wong N, Brunet JS, Narod SA. BRCA mutations and survival in breast cancer. J Clin Oncol 1998;16:3206-8.
314. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ, et al. Germline BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997;3:2465-9.
315. Foulkes WD, Wong N, Rozen F, Brunet JS, Narod SA. Survival of patients with breasl cancer and BRCA1 mutations. Lancet 1998;351:1359-60.
316. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000;11:307-13.
317. Loman N, Johannsson O, Bendahl P, Dahl N, Einbeigi Z, Gerdes A, et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer 2000;36:1365-73.
318. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
319. Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000;83:384-6.
320. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-72.
321. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9.
322. Chang-Claude J, Becher H, Eby N, Bastert G, Wahrendorf J, Hamann U. Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol 1997;123:272-9.
323. Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995;64:394-8.
324. Jemstrom HC, Johannsson OT, Loman N, Borg A, Olsson H. Reproductive factors in hereditary breast cancer. Breast Cancer Res Treat 1999;58:295-301.
325. Jemstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999;354:1846-50.
326. Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998;352:1359-60.
327. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.
328. Eisen A, Rebbeck TR, Lynch HT, Lerman C, Ghadirian P, Dube MP, et al. Reduction in breast cancer risk following bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2000;67(suppl):58.
329. Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 1998;90:761-6.
330. Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997;57:3678-81.
331. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995;11:428-33.
332. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996;12:309-11.
333. Hubert A, Peretz T, Manor O, Kaduri L, Wienberg N, Lerer I, et al. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer [letter]. Am J Hum Genet 1999;65:921-4.
334. Nastiuk KL, Mansukhani M, Terry MB, Kularatne P, Rubin MA, Melamed J, et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999;40:172-7.
335. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 2000;60:1371-5.
336. Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 2000;83:463-6.
337. Wilkens EP, Freije D, Xu J, Nusskem DR, Suzuki H, Isaacs SD, et al. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 1999;39:280-4.
338. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999;35:1248-57.
339. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjord JE, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997;75:758-61.
340. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II, BRCA1 and BRCA2: Cancer Genetics Studies Consortium [see comments]. JAMA 1997;277:997-1003.
341. Eisinger F, Alby N, Bremond A, Dauplat J, Espie M, Janiaud P, et al. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 1998;9:939-50.
342. Annab LA, Terry L, Cable PL, Brady J, Stampfer MR, Barrett JC, et al. Establishment and characterization of a breast cell strain containing a BRCA1 185delAG mutation. Gynecol Oncol 2000;77:121-8.
343. Tilanus-Linthorst MM, Bartels CC, Obdeijn AIM, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000;36:514-9.
344. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, van Geel AN, Menke M, Seynaeve C, et al. Breast cancer risk after prophylactic mastectomy in BRCA1/2 mutation carriers [abstract]. Proc Am Soc Clin Oncol 2000;19:608.
345. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US-diagnostic yield and tumor characteristics. Radiology 1998;207:191-9.
346. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000;215:267-79.
347. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-32.
348. van Nagell JR, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-6.
349. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
350. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial [see comments]. Lancet 1998;352:98-101.
351. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer: Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-8.
352. Martin A-M, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 2000;92:1126-35.
353. Dupont WD, Plummer WD. Understanding the relationship between relative and absolute risk. Cancer 1996;77:193-9.
354. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1999;90:1371-88.
355. Gail MH, Brinton LH, Byar DP, Corle DK, Green SB, Schairer C, et al. Developing individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
356. Veronesi U, Saccozzi R, Del Vecchio M. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
357. Veronesi U, Salvadori B, Luini A, Banff A, Zucali R, Del Vecchio M, et al. Conservative treatment of early breast cancer: long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg 1990;211:250-9.
358. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer [see comments]. N Engl J Med 1995;333:1456-61.
359. Fisher B, Bauer M, Margolese R, Poisson R, Pilch J, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with and without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
360. Fisher B, Redmond C, Poisson R. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-8.
361. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337:956-62.
362. Overgaard M, Hansen PS, Overgaard J, Rose C, Anderson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997;337:949-55.
363. Brekelmans CT, Voogd AC, Botke G, van Geel BN, Rodrigus P, Rutgers EJ, et al. Family history of breast cancer and local recurrence after breast-conserving therapy: the Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Eur J Cancer 1999;35:620-6.
364. Haas JA, Schultz DJ, Peterson ME, Solin LJ. An analysis of age and family history on outcome after breast-conservation treatment: the University of
365. Chabner E, Nixon A, Gelman R, Hetelekidis S, Recht A, Bomstein B, et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1998;16:2045-51.
366. Harrold EV, Turner BC, Matloff ET, Pathare P, Beinfield M, McKhann C, et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history [see comments]. Cancer J Sci Am 1998;4:302-7.
367. Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 1999;17:3017-24.
368. Kurtz JM, Amalric R, Brandone H, Ayme Y, Spitalier J-M. Contralateral breast cancer and other second malignancies in patients treated by breast-conserving therapy with radiation. Int J Radiat Oncol Biol Phys 1988;15:277-84.
369. Hicken N. Mastectomy: a clinical pathologic study demonstrating why most mastectomies result in incomplete removal of the mammary gland. Arch Surg 1940;40:6-14.
370. Goldman LD, Goldwyn RM. Some anatomical considerations of subcutaneous mastectomy. Plast Reconstr Surg 1973;51:501-5.
371. Temple WJ, Lindsay RL, Magi E, Urbanski SJ. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg 1991;161:413-5.
372. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 1984;148:692-3.
373. Goodnight JE, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984;26:198-201.
374. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991;14:451-4.
375. Bowers DG, Radlauer CB. Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with silicone prostheses. Plast Reconstr Surg 1969;44:541-4.
376. Holleb Al, Montgomery R, Farrow JH. The hazard of incomplete simple mastectomy. Surg Gynecol Obstet 1965;121:819-22.
377. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989;13:15-21.
378. Fisher J, Maxwell P, Woods J. Surgical alternatives in subcutaneous mastectomy reconstruction. Clin Plast Surg 1988;15:667-76.
379. Woods JE. Subcutaneous mastectomy: current state of the art. Ann Plast Surg 1983;11:541-50.
380. Woods JE. Detailed technique of subcutaneous mastectomy with and without mastopexy. Ann Plast Surg 1987;18:51-61.
381. Freeman BS, Wiemer DR. Total glandular mastectomy: modifications of the subcutaneous mastectomy for use in premalignant disease of the breast. Plast Reconstr Surg 1978;62:167-72.
382. Horton CE, Dascombe WH. Total mastectomy: indications and techniques. Clin Plast Surg 1988;15:677-87.
383. Carlson GW, Bostwick J III, Styblo TM, Moore B, Bried JT, Murray DR, et al. Skin-sparing mastectomy: oncologic and reconstructive considerations. Ann Surg 1997;225:570-8.
384. Newman LA, Kuerer HM, Hunt KK, Kroll SS, Ames FC, Ross MI, et al. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol 1998;5:620-6.
385. Hidalgo DA, Borgen PI, Petrek JA, Heerdt AH, Cody HS, Disa JJ. Immediate reconstruction after complete skin-sparing mastectomy with autologous tissue. J Am Coll Surg 1988;187:17-21.
386. Simmons RM, Fish SK, Gayle L, La Trenta GS, Swistel A, Christos P, et al. Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. Ann Surg Oncol 1999;6:676-81.
387. Klamer TW, Donegan WL, Max MH. Breast tumor incidence in rats after partial mammary resection. Arch Surg 1983;118:933-5.
388. Wong JH, Jackson CF, Swanson JS, Palmquist MA, Oyama AA, Miller SH, et al. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7,12-dimethylbenzanthracene-induced breast cancer. Surgery 1986;99:67-71.
389. Nelson H, Miller SH, Buck D, Demuth RJ, Fletcher WS, Buehler P. Effectiveness of prophylactic mastectomy in the prevention of breast tumors in C3H mice. Plast Reconstr Surg 1989;83:662-9.
390. Baasch M, Nielsen SF, Engholm G, Lund K. Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 1996;73:961-3.
391. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
392. Hartmann LC, Schaid D, Sellers TA, McDonnell SK, Woods JE, Sitta DL, et al. Bilateral prophylactic mastectomy (PM) in BRCA1/2 mutation carriers [abstract]. Proc Am Assoc Cancer Res 2000;41.
393. Foote FW, Stewart FW. Comparative studies of cancerous versus noncancerous breasts. Ann Surg 1945;121:197-222.
394. Robbins GF, Berg JW. Bilateral primary breast cancers. A prospective clinicopathologic study. Cancer 1964;17:1501-27.
395. Leis HP. Selective, elective, prophylactic contralateral mastectomy. Cancer 1971;28:956-61.
396. Ringberg A, Palmer B, Linell F. The contralateral breast at reconstructive surgery after breast cancer operation: a histopathologic study. Breast Cancer Res Treat 1982;2:151-61.
397. Beller FK, Nienhaus H, Niedner W, Holzgreve W. Bilateral breast cancer: the frequency of undiagnosed cancers. Am J Obstet Gynecol 1986;155:247-55.
398. Hoffman E. The contralateral breast in ipsilateral breast carcinoma. South Med J 1990;83:1009-15.
399. Gershenwald JE, Hunt KK, Kroll SS, Ross MI, Baldwin BJ, Feig BW, et al. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol 1998;5:529-38.
400. Lee JS, Grant CS, Donohue JH, Crotty TB, Harmen WS, Ilstrup DM. Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 1995;118:640-7.
401. Staren ED, Robinson DA, Witt TR, Economou SG. Synchronous, bilateral mastectomy. J Surg Oncol 1995;59:75-9.
402. Cody HS. Routine contralateral breast biopsy: Helpful or irrelevant? Experience in 871 patients, 1979-1993. Ann Surg 1997;225:370-6.
403. Rosen PP, Groshen S, Kinne DW, Hellman S. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1NOM0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery 1989;106:904-10.
404. Rosen PP, Groshen S, Kinne DW. Prognosis in T2NOM0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991;9:1650-61.
405. Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results [see comments]. Cancer 1997;79:2219-28.
406. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation [In Process Citation]. Lancet 2000;355:2015-20.
407. Eisinger F, Claire J-R, Sobol H, Stoppa-Lyonnet D, Lasset C, Nogues C. Acceptability of prophylactic mastectomy in cancer-prone women. JAMA 2000;283:202-3.
408. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 1995;24:412-9.
409. Montgomery LL, Tran KN, Heelan MC, Van Zee KJ, Massie MJ, Payne DK, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 1999;6:546-52.
410. Borgen PI, Hill AD, Tran KN, Van Zee KJ, Massie MJ, Payne D, et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998;5:603-6.
411. Payne DK, Biggs C, Tran KN, Borgen PI, Massie MJ. Women's regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 2000;7:150-4.
412. Frost MH, Schaid DJ, Sellers TA, Slezak JM, Arnold PC, Woods JE, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000;284:319-24.
413. Querleu D, Chapron C, Chevallier L, Bruhat MA. Complications of gynecologic laparoscopic surgery: a French multicenter collaborative study [letter]. N Engl J Med 1993;328:1355.
414. Brinton LA, Schairer C, Hoover RN, et al. Menstrual factors and risk of breast cancer. Cancer Invest 1988;6:245-54.
415. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Monogr Natl Cancer Inst 1995;17:33-5.
416. Fromm GL, Gershenson DM, Silva DG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89-95.
417. Zhou J, Iwasa Y, Konishi L. Papillary serous carcinoma of the peritoneum in women: a clinicopathologic and immunohistochemical study. Cancer 1995;76:429-36.
418. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer 1993;71:2751-5.
419. Weber BL, Punzalan C, Eisen A, Lynch HT, Narod SA, Garber JE, et al. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers [abstract]. Am J Hum Genet 2000;67(suppl):59.
420. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71.
421. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000;283:617-24.
422. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1- positive or BRCA2-positive patients [see comments]. J Clin Oncol 1998;16:979-85.
423. Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, et al. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am 2000;6:13-20.
424. Eisinger F, Nogues C, Bimbaum D, Jacquemier J, Sobol H. Low frequency of lymph-node metastasis in BRCA1-associated breast cancer [letter]. Lancet 1998;351:1633-4.
425. Robson ME, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642-9.
426. Loman N, Johannsson O, Bendahl PO, Borg A, Femo M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310-9.
427. Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J, et al. Predicted antioestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998;34:1683-6.
428. Schlichtholz B, Bouchind'homme B, Pages S, Martin E, Liva S, Magdelenat H, et al. p53 mutations in BRCA1-associated familial breast cancer [letter]. Lancet 1998;352:622.
429. Eisinger F, Nogues C, Guinebretiere JM, Peyrat JP, Bardou VJ, Noguchi T, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 1999;84:263-7.
430. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes [see comments]. JAMA 1996;275:1885-92.
431. Robson M, Levin D, Brown K, Haas B, Hampel H, Schulz C, et al. Results of breast conservation therapy (BCT) for invasive breast cancer in women with BRCA mutations [abstract]. Proc Am Soc Clin Oncol 1998;17:548.